William H. Carson

William (Bill) H. Carson, M.D., was appointed Decibel’s Chairman of the Board of Directors in May 2021. Bill was most recently the President and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), leading the development and regulatory approvals of Otsuka’s global compounds including Abilify Maintena®, Rexulti®, Samsca®, and Jynarque®. He also oversaw the approval of Abilify MyCite®, the first FDA-approved digital medicine. Bill serves as Chairman of the Board of Directors of OPDC and is also the Chairman of the Board of the Sozosei Foundation, a newly established Otsuka charitable organization focused on decriminalization of mental illness. He serves on the boards of Excision BioTherapeutics, Saama, and Annexon Biosciences, and as a Trustee of the non-profit Internet2. He is Board Chair Emeritus of the Sphinx Organization, which advocates for parity and inclusion in the arts. Bill holds an A.B. degree from Harvard College and earned his medical degree from Case Western Reserve University School of Medicine. He completed his residency training in psychiatry at Tufts University School of Medicine. He is a Distinguished Fellow of the American Psychiatric Association, the National Medical Association, and the Executive Leadership Council.